Post-Traumatic Stress Disorder (PTSD) is a serious condition that occurs in people who have experienced or witnessed a life-threatening event, such as a natural disaster, serious accident, terrorist incident, sudden death of a loved one, war, rape, or other violent personal assault. The fear due to such incidents triggers many split-second changes in the body, which protect the body in adverse situations.

Download free sample copy of report at: https://www.pharmaproff.com/request-sample/1238

PTSD is not diagnosed unless the symptoms last for at least one month. In order to be diagnosed with PTSD, a person must have three different types of symptoms: re-experiencing symptoms, avoidance and numbing symptoms, and arousal symptoms. Cognitive behavioral therapy (CBT) and family therapy are some of the therapies used to treat PTSD. ZOLOFT (by Pfizer Inc.), a selective serotonin reuptake inhibitor (SSRI), is being used for the treatment of PTSD.

According to the research findings, majority of the pipeline drug candidates are being developed to be administered by oral route. It has been observed that the oral route of medication is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance. Administration of therapeutics for PTSD through oral route has shown promising results in clinical studies.
Companies that are involved in developing therapeutics for PTSD have shown positive clinical results in the various phases of drug development. For instance, BNC210, a negative allosteric modulator of the A7 nicotinic acetylcholine receptor, is being developed by Bionomics Limited to treat patients with PTSD. The results from the phase II trial of BNC210 showed that BNC210 was safe and well tolerable in patients with PTSD.

















Get the detailed analysis at: https://www.pharmaproff.com/report/ptsd-therapeutics-pipeline-analysis


H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co. Ltd. (Otsuka) entered into an agreement to develop and commercialize five innovative products in the field of psychiatry and neuroscience. In November 2018, Lundbeck and Otsuka reported positive phase II data from the combination treatment of brexpiprazole and sertraline for the treatment of PTSD.
Bionomics Limited, Pfizer Inc., India Globalization Capital Inc., Therapade Technologies LLC, Axim Biotechnologies Inc., H. Lundbeck A/S, and Otsuka Pharmaceutical Co. Ltd. are some of the major companies involved in the development of drug candidates for the treatment of PTSD.
The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of PTSD. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the PTSD therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to PTSD.

Vaginitis refers to the inflammation of vagina. It affects women of all ages but is most common during the reproductive years. Vaginitis occurs due to change in the balance of the yeast and bacteria that normally live in the vagina.


Download the sample report @ https://www.pharmaproff.com/request-sample/1151



















This causes the lining of the vagina to become inflamed. Use of antibiotics, changes in hormone levels due to pregnancy, breastfeeding, menopause, douching, spermicides, sexual intercourse and infection can change the normal balance of the vagina.

Get the detailed analysis @ https://www.pharmaproff.com/report/vaginitis-therapeutics-pipeline-analysis

The main symptom of vaginitis is increased discharge with a strong fishy odour. Itching is not common, but may be present if there is a lot of discharge. Vaginitis can be diagnosed by taking a sample of the discharge from vagina, which is then observed under a microscope. The treatment depends on the cause of the vaginitis. It may include a pill or a cream or gel that is applied to the vagina.

The drug candidates in vaginitis pipeline include, but are not limited to, Polygynax and Tamoxifen vaginal. Some of the companies in vaginitis therapeutics pipeline are Lumavita AG and Fulhold Pharma Limited.

Androgenetic alopecia is a genetic disorder of patterned hair loss that affects both men and women. The disorder shortens hair growth cycle due to excess of androgen, which eventually delays hair growth. Some of the major symptoms include gradual recession of frontal hairline, increased hair fall, bitemporal recession of hair, and thinning of the hair. The symptoms start appearing at the age of 20 and are seen to be prominent in people aged 40 years and above. The disorder leads to hair thinning near crown region, and maybe caused due to various genetic as well as environmental factors. The disorder can also occur due to hormonal imbalance, improper functioning of androgen hormones, poor diet, and excessive smoking.


Download the sample report at: https://www.pharmaproff.com/request-sample/1234

 
















Androgenetic alopecia can diagnose with the help of blood tests, thyroid tests, biopsy, transferrin iron-binding capacity, Norwood Hamilton Scale assessment in men, and dehydroepiandrosterone sulfate (DHEAS) and testosterone analysis in women. The disorder can be treated by surgical transplantation, medical procedures, and low-level light therapy.
Propecia is one of the key U.S. Food and Drug Administration (USFDA) approved drugs, developed by Merck & Co. Inc., for the treatment of androgenetic alopecia in men.

Browse Detailed Report at: https://www.pharmaproff.com/report/androgenic-alopecia-therapeutics-pipeline-analysis


According to the research, many drugs being developed for androgenetic alopecia, which are administered topically. It has been found that topical route of administration is easy to use, non-invasive, and ensures high level of patient satisfaction.

There are several companies which have shown positive results of clinical trials. For instance, in February 2019, Cassiopea SpA announced effective result of Phase II clinical trial of Breezula for treatment of androgeneticalopecia.

It has been observed that many pharmaceutical companies are developing new and improved technologies for the development of androgenetic alopecia therapeutics. These technologies play an important role in the drug development by helping the companies to develop more specific and effective targeted therapies. For instance, RepliCel Life Sciences is using its proprietary cell therapy technology to develop therapeutic candidates for pattern baldness and other disorders. It utilizes dermal sheath cup cells, which induce the growth of cells in the area of baldness.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1234

Samumed LLC, Brickell Biotech Inc., Aclaris Therapeutics Inc., Cassiopea S.p.A, Kerastem Technologies LLC, Almirall S.A., and RepliCel Life Sciences are the major players involved in the development of drug candidates for the treatment of androgenetic alopecia.